Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 208411
Company: EMERGENT
Company: EMERGENT
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| NARCAN | NALOXONE HYDROCHLORIDE | 4MG/SPRAY | SPRAY, METERED;NASAL | Over-the-counter | None | Yes | Yes |
| NARCAN | NALOXONE HYDROCHLORIDE | 2MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SPRAY, METERED;NASAL | Discontinued | None | Yes | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 11/18/2015 | ORIG-1 | Approval | Type 3 - New Dosage Form | PRIORITY |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/208411Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208411Orig1s000TOC.html |
Supplements
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
|---|---|---|---|---|---|
| 02/11/2026 | SUPPL-11 | Labeling-Container/Carton Labels |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208411Orig1s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/208411Orig1s011ltr.pdf | |
| 01/09/2026 | SUPPL-10 | Labeling-Container/Carton Labels |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208411Orig1s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/208411Orig1s010ltr.pdf | |
| 11/21/2025 | SUPPL-9 | Labeling-Container/Carton Labels, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208411Orig1s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/208411Orig1s009ltr.pdf | |
| 03/27/2023 | SUPPL-7 | Labeling-Patient Package Insert, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208411s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/208411Orig1s007ltr.pdf | |
| 03/29/2023 | SUPPL-6 | Efficacy-Rx To OTC Switch |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208411Orig1s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/208411Orig1s006ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/208411Orig1s006TOC.html | |
| 08/06/2020 | SUPPL-4 | Manufacturing (CMC)-Expiration Date |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208411Orig1s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208411Orig1s004ltr.pdf | |
| 09/23/2019 | SUPPL-2 | Labeling-Package Insert |
Label (PDF)
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208411Orig1s002lbl.pdf | |
| 01/24/2017 | SUPPL-1 | Efficacy-Manufacturing Change With Clinical Data |
Label (PDF)
Letter (PDF) Summary Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208411s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208411Orig1s001ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2017/208411s001SumR.pdf |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 02/11/2026 | SUPPL-11 | Labeling-Container/Carton Labels | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208411Orig1s011lbl.pdf | |
| 01/09/2026 | SUPPL-10 | Labeling-Container/Carton Labels | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208411Orig1s010lbl.pdf | |
| 11/21/2025 | SUPPL-9 | Labeling-Container/Carton Labels | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208411Orig1s009lbl.pdf | |
| 11/21/2025 | SUPPL-9 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208411Orig1s009lbl.pdf | |
| 03/29/2023 | SUPPL-6 | Efficacy-Rx To OTC Switch | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208411Orig1s006lbl.pdf | |
| 03/27/2023 | SUPPL-7 | Labeling-Patient Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208411s007lbl.pdf | |
| 03/27/2023 | SUPPL-7 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208411s007lbl.pdf | |
| 08/06/2020 | SUPPL-4 | Manufacturing (CMC)-Expiration Date | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208411Orig1s004lbl.pdf | |
| 09/23/2019 | SUPPL-2 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208411Orig1s002lbl.pdf | |
| 01/24/2017 | SUPPL-1 | Efficacy-Manufacturing Change With Clinical Data | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208411s001lbl.pdf | |
| 11/18/2015 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf |
NARCAN
The products listed here are over-the-counter (OTC) drugs and do not receive therapeutic equivalence ratings. They may not be interchangeable.
SPRAY, METERED;NASAL; 4MG/SPRAY
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | Application No. | Company |
|---|---|---|---|---|---|---|---|
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | 4MG/SPRAY | SPRAY, METERED;NASAL | Over-the-counter | No | 217992 | AMNEAL |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | 4MG/SPRAY | SPRAY, METERED;NASAL | Over-the-counter | No | 211951 | PADAGIS ISRAEL |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | 4MG/SPRAY | SPRAY, METERED;NASAL | Over-the-counter | No | 209522 | TEVA PHARMS USA |
| NARCAN | NALOXONE HYDROCHLORIDE | 4MG/SPRAY | SPRAY, METERED;NASAL | Over-the-counter | Yes | 208411 | EMERGENT |